|1.||Cui, Zhengrong: 2 articles (07/2013 - 03/2013)|
|2.||Wonganan, Piyanuch: 2 articles (07/2013 - 03/2013)|
|3.||Zhu, Saijie: 2 articles (07/2013 - 03/2013)|
|4.||Lansakara-P, Dharmika S P: 2 articles (07/2013 - 03/2013)|
|5.||Soo, Ross A: 2 articles (12/2008 - 07/2008)|
|6.||Holford, Nicholas H G: 2 articles (12/2008 - 07/2008)|
|7.||Goh, Boon-Cher: 2 articles (12/2008 - 07/2008)|
|8.||Lee, How-Sung: 2 articles (12/2008 - 07/2008)|
|9.||Lee, Soo-Chin: 2 articles (12/2008 - 07/2008)|
|10.||Tham, Lai-San: 2 articles (12/2008 - 07/2008)|
11/01/2006 - "A new, simple method for quantifying gemcitabine triphosphate in cancer cells using isocratic high-performance liquid chromatography."
02/01/2001 - "Tumor incorporation of gemcitabine triphosphate (dFdCTP) was measured to assess whether adequate concentrations were achieved at each dose level. "
07/10/2013 - "We substantiated that it is the way the 4-(N)-GemC18-SLNs deliver the 4-(N)-GemC18 into tumor cells that allows the gemcitabine hydrolyzed from the 4-(N)-GemC18 to be more efficiently converted into its active metabolite, gemcitabine triphosphate (dFdCTP), and thus more potent against gemcitabine-resistant tumor cells than 4-(N)-GemC18 or gemcitabine alone. "
03/01/2013 - "Furthermore, GemC18 loaded in the highly acid-sensitive PHC-2 micelles inhibited the expression of RRM1 and increased the level of gemcitabine triphosphate (dFdCTP) in gemcitabine resistant tumor cells. "
07/01/2008 - "Gemcitabine amount in the body and area under the concentration-time curves of plasma gemcitabine, 2',2'-difluorodeoxyuridine, and intracellular gemcitabine triphosphate in white cells were compared to determine which best describes tumor shrinkage over time. "
|2.||Melanoma (Melanoma, Malignant)
04/01/2006 - "In this study, the plasma pharmacokinetics of gemcitabine and its inactive metabolite, 2',2'-difluorodeoxyuridine (dFdU), were investigated in dogs after intravenous bolus gemcitabine doses of 3, 10, and 30 mg/kg. Furthermore, the intracellular accumulation of the active metabolite gemcitabine triphosphate, as a surrogate pharmacodynamic endpoint, was also determined in vitro in canine melanoma cells. "
|3.||Lung Neoplasms (Lung Cancer)
|4.||Sarcoma (Soft Tissue Sarcoma)
08/01/2001 - "Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation."
11/15/2004 - "Phase I clinical trial of fixed-dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation."
08/01/2001 - "To evaluate the efficacy, toxicity, and optimal dose rate of gemcitabine in adult patients with advanced soft tissue sarcomas (STS) by comparing levels of gemcitabine triphosphate (GTP) in peripheral-blood mononuclear cells (PBMCs) of patients receiving two different dose rates. "
|5.||Pancreatic Neoplasms (Pancreatic Cancer)
04/01/2013 - "Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy."
08/15/2002 - "Recent applications have included the use of a fixed-dose rate regimen in patients with advanced pancreatic cancer based on the observation that deoxycytidine kinase is saturated at the plasma gemcitabine concentrations achieved with standard infusion, thereby limiting the accumulation of intracellular gemcitabine triphosphate. "
|3.||Ribonucleotide Reductases (Ribonucleotide Reductase)
|5.||Guanosine Triphosphate (GTP)
|6.||DNA (Deoxyribonucleic Acid)
|9.||DNA ligase (ATP)